Early drug study tracks MS Candidate's journey through the body

NCT ID NCT04171310

Completed Knowledge-focused Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage study gave a single oral dose of a radioactive form of the experimental drug SAR442168 to 6 healthy men. Researchers measured how much of the drug was excreted in urine and stool, and how it moved through the bloodstream. The goal was to understand the drug's metabolism and elimination, which is essential before testing it in people with multiple sclerosis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SAR442168 (oral solution)
What this could lead to: If successful, this study will help researchers understand how SAR442168 is absorbed and eliminated, which is a step toward developing a treatment for multiple sclerosis.
What could go wrong: This is a very early, small study in just 6 healthy men, not patients. It only looks at how the drug moves through the body, not whether it works for MS. Results may not predict effectiveness or safety in patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

Investigational Site Number 8260001

Nottingham, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.